Immune Therapeutics Profitability Analysis

IMUN -  USA Stock  

USD 2.17  0.53  19.63%

For Immune Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Immune Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Immune Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Immune Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Immune Therapeutics over time as well as its relative position and ranking within its peers. Please see Risk vs Return Analysis.

Immune Current Profitability Trends 

 
Refresh
Is Immune Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immune Therapeutics. If investors know Immune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immune Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Immune Therapeutics is measured differently than its book value, which is the value of Immune that is recorded on the company's balance sheet. Investors also form their own opinion of Immune Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Immune Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immune Therapeutics' market value can be influenced by many factors that don't directly affect Immune Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immune Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine Immune Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immune Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Immune Therapeutics Price to Book vs. Current Liabilities Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Immune Therapeutics's current stock value. Our valuation model uses many indicators to compare Immune Therapeutics value to that of its competitors to determine the firm's financial worth.
Immune Therapeutics is rated fourth overall in current liabilities category among related companies. It is currently regarded as number one stock in price to book category among related companies . The ratio of Current Liabilities to Price to Book for Immune Therapeutics is about  177,231 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Immune Therapeutics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Immune Therapeutics' OTC Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Immune Therapeutics' earnings, one of the primary drivers of an investment's value.

Immune Price to Book vs. Current Liabilities

Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Immune Therapeutics 
Current Liabilities 
 = 
Payables 
Accrued Debt 
7.49 M
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
Immune Therapeutics 
P/B 
 = 
MV Per Share 
BV Per Share 
42.25 X
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.

Immune Price to Book Comparison

Immune Therapeutics is currently under evaluation in price to book category among related companies.

Immune Therapeutics Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Immune Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Immune Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Immune Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Immune Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Immune Therapeutics, Inc. focuses on the development, approval, and commercialization of pharmaceutical products. Immune Therapeutics, Inc. was incorporated in 1993 and is headquartered in Orlando, Florida. Immune Therapeutics operates under Biotechnology classification in the United States and is traded on OTC Exchange.

Immune Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Immune Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Immune Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Immune Therapeutics' important profitability drivers and their relationship over time.

Use Immune Therapeutics in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Immune Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Immune Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Immune Therapeutics Pair Trading

Immune Therapeutics Pair Trading Analysis

Correlation analysis and pair trading evaluation for Immune Therapeutics and Csl. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  

Use Investing Themes to Complement your Immune Therapeutics position

In addition to having Immune Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Energy Thematic Idea Now

Energy
Energy Theme
Funds or Etfs investing in energy sector, natural resources, and ecology. Energy theme has 40 constituents.
View All  Next Launch Energy
Please see Risk vs Return Analysis. Note that the Immune Therapeutics information on this page should be used as a complementary analysis to other Immune Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.

Complementary Tools for Immune OTC Stock analysis

When running Immune Therapeutics price analysis, check to measure Immune Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immune Therapeutics is operating at the current time. Most of Immune Therapeutics' value examination focuses on studying past and present price action to predict the probability of Immune Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Immune Therapeutics' price. Additionally, you may evaluate how the addition of Immune Therapeutics to your portfolios can decrease your overall portfolio volatility.
ETF Directory
Find actively traded Exchange Traded Funds (ETF) from around the world
Go
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Go
Stock Screener
Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Go
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Go
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Go
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Go
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Go
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Go
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
To fully project Immune Therapeutics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Immune Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Immune Therapeutics' income statement, its balance sheet, and the statement of cash flows.
Potential Immune Therapeutics investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Immune Therapeutics investors may work on each financial statement separately, they are all related. The changes in Immune Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Immune Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.